FDA approves Xywav to treat cataplexy or excessive daytime sleepiness in patients with narcolepsy.- Jazz Pharma
Related news and insights
Jazz Pharmaceuticals plc announced the Health Canada approval and availability of Sunosi (solriamfetol) for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA) in adult patients. Once-daily?Sunosi?is approved with doses of 75 mg and 150 mg. Sunosi?is the first dopamine and norepinephrine reuptake inhibitor (DNRI) approved to treat EDS in adults living with narcolepsy or OSA. EDS?is characterized by the inability to stay awake and alert during the day resulting in unplanned lapses into sleep or drowsiness.
Jazz Pharmaceuticals plc announced the publication of the global Phase III double-blind, placebo-controlled, randomized-withdrawal, multicenter study of Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution, for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.
Jazz Pharmaceuticals plc announced that the FDA approved Xywav (calcium, magnesium, potassium, and sodium oxybate) oral solution on July 21, 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.